Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced reduced effectiveness of minoxidil after consistent use, despite using dutasteride to maintain hair. They are considering alternatives like microneedling and exploring options like hair transplants due to dissatisfaction with current hair density.

The user experienced hair shedding after starting testosterone replacement therapy (TRT) and is considering using DHT blockers like finasteride or dutasteride to address potential DHT-related hair loss. Low ferritin levels due to frequent blood donations may also contribute to hair issues, and the user is working on stabilizing iron levels.

A user wants to dilute a melatonin sublingual spray to 0.0033% for use as a topical hair loss treatment. They ask if distilled water can be used for dilution and how much is needed for stability over months.

The user is experiencing scalp itching despite using finasteride and Ketoconazole shampoo for hair loss and seborrheic dermatitis. They are unsure if the itch is due to their treatments, diet, or mental factors.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user switched from topical to oral finasteride and minoxidil for hair loss and experienced swelling and sensitivity in the left chest area. They are concerned about these symptoms but noticed improvement after skipping a dose.

The conversation discusses the use of topical minoxidil for hair loss and the potential benefits of taking a Minoxidil Response Test to determine enzyme activity related to its effectiveness. Some users have considered or tried alternatives like oral minoxidil or tretinoin, with mixed experiences regarding side effects and effectiveness.

The conversation discusses a comparison table for a spray combining Minoxidil and Finasteride for hair loss treatment in the UK. Specific treatments mentioned are Minoxidil (Min) and Finasteride (Fin).

The conversation discusses enhancing Minoxidil absorption for hair loss treatment using Tretinoin and MSM (Methylsulfonylmethane). The user is seeking sources for Tretinoin and mentions MSM's potential to improve the absorption of topical agents.

Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

A user accidentally ingested minoxidil instead of melatonin, leading to a humorous discussion about similar mix-ups and the effects of minoxidil. The user now stores the bottles separately to avoid future mistakes.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

The conversation discusses hair transplant experiences and decisions, focusing on whether individuals would choose the same doctor again. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user has been using topical minoxidil 5% with finasteride 0.1% for two years and is considering whether to continue with this or try new minoxidil variations available in the market. They are seeking advice on which option might be more effective.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The conversation is about finding a precise scale for measuring melatonin. The user needs to add 5mg per 100ml and finds Amazon scales imprecise.

A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The conversation discusses hair loss treatments, focusing on finasteride, dutasteride, and minoxidil. The user is considering adding minoxidil to their regimen after using finasteride and dutasteride without significant results, while others suggest minoxidil is essential for diffuse thinning.

The conversation discusses the effectiveness of different concentrations and dosages of topical finasteride on scalp and serum DHT levels, comparing it to oral finasteride and noting the side effects seem to be fewer at lower dosages. Participants shared experiences and referenced a chart indicating similar scalp DHT reduction with 0.025% topical finasteride as with 1mg oral finasteride, but with fewer side effects.

User discusses topical liposomal finasteride for hair loss, hoping to avoid breast growth side effect. Conversation includes using minoxidil, fluridil, and dermarolling, and mentions minimal systemic absorption of liposomal finasteride.

The post is about using different solutions for RU58841, a treatment for hair loss. The user is asking for opinions on the effectiveness of different vehicles and dosages.

The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.

The conversation is about someone who initially had positive results with Minoxidil for hair loss, lost those gains due to a hospital stay, and is now not seeing the same results upon resuming treatment. They plan to add microneedling and/or tretinoin to their regimen and are seeking success stories from others who did not respond to Minoxidil alone.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The user is unsure if their hair has improved or worsened after inconsistent minoxidil use, iron, and vitamin D supplements. A reply suggests the hair looks better but recommends consistent photo angles for accurate comparison.

Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.